Publications List

1. Aguilar-Navarro AG, Edun G, Gower M, Kant J, Li X, Yang D, Nader M, Fernandez M, Jahangiri S, Tsao E, Joshi P, Kossinna P, Caloren LC, Davey JR, Zywiel MG, Suderman RP, Kapoor AI, Akens MK, Changoor A, Woo M, Stanley RF, Young KA, Tran C, Sotov V, Wang BX, Abelson S, Abdel-Wahab O, Naik S, Trowbridge JJ, Vanner R, Hope KJ, Tsui H, Gaiti F, Tikhonova AN. Prefibrotic bone marrow microenvironment is a hallmark of clonal hematopoiesis. Nat Immunol. 2026 Sep 30. Epub ahead of print.
2. Zheng EYF, Wang CH, Ochi T, Ohashi Y, Ihara F, Fukao S, Ito Y, Boukhaled GM, Wang BX, Han DH, Wei X, Yolmo P, Burt BD, Saso K, Matsunaga Y, Ly D, Kagoya Y, Butler MO, Minden MD, Hirano N. CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles. Blood Cancer Discov. 2026 Sep 3;7(5):813-828.
3. Veneziani AC, Lheureux S, Millar DG, Dhani N, Colombo I, Madariaga A, Soberanis Pina P, Atale S, Chan YL, Lee J, Ramsahai J, Quintos J, Wang L, Li X, Bowering V, Ohashi P, Wang B, Oza AM. Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial. Nat Commun. 2026 May 14;17(1):6416.
4. Strum S, Murray C, Genta S, Sanz-Garcia E, Razak A, Lheureux S, Pipinikas C, Wang BX, Chevalier A, Smith CG, Spreafico A, Siu LL, Elliott M, Cescon DW. Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay. Int J Mol Sci. 2026 Apr 29;27(9):3979.
5. Ihara F, Ohashi Y, Zheng EYF, Fukao S, Rodrigo R, Noamani B, Boukhaled GM, Wang BX, Han DH, Wei X, Burt BD, Saso K, Matsunaga Y, Ly D, Kagoya Y, Butler MO, Mak TW, Saibil SD, Hirano N. CD28-driven ex vivo generation of stem-like memory CD8⁺ T cells bypassing CD3/TCR signaling. Proc Natl Acad Sci U S A. 2026 Apr 28;123(17):e2524626123.
6. Gorrini C, Jafari S, Duncan G, Snow B, Hendrikse L, McLoughlin L, Haight J, Wakeham A, Tobin C, Elia A, Ramachandran P, Law R, Gang B, Lu TL, Morgado-Palacin I, You-Ten A, Berger T, Sordella R, Mak TW. Unveiling the developmental and tumor-suppressive roles of the p53 variant p53psi. Proc Natl Acad Sci U S A. 2026 Mar 31;123(13):e2427242123.
7. Said BI, Boukhaled GM, Lok BH, Lukovic J, Mesci A, Waldron J, Wong P, Wang BX, Brooks DG, Milosevic M. Cross-Cancer Analysis Reveals a Distinct Pattern of Immune Modulation During Curative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2026 Feb 1;124(2):441-450.
8. Rose AAN, Maxwell J, Rousselle E, Mukonoweshuro CL, Elkholi IE, Riaud M, Biondini M, Cianfarano E, Soria-Bretones I, Tobin C, McGuire M, Law RWY, Elia AJ, Wang BX, King I, Zhang T, Pugh TJ, Kamil ZS, Butler M, Shepherd FA, Leighl NB, Razak AA, Hansen A, Saibil SD, Bedard PL, Siegel PM, Siu LL, Cescon DW, Spreafico A. Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial. Nat Commun. 2026 Jan 3;17(1):1323.
9. O'Kane GM, Mesci A, Jang RW, Barry A, Bocaya CM, Boukhaled GM, Acton H, Doddington D, Rodrigo R, Chan LML, Noamani B, Harvey H, Elia A, Law R, Prince R, Doherty M, Dodd A, Wong DK, Wang L, Wang BX, Chen EX, Dawson LA, Knox JJ. Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib - A phase II trial (PEMRAD). JHEP Rep. 2025 Nov 1;8(2):101658.
10. Garg V, Prokopec SD, Stone SC, Pakbaz S, Chen ML, Lam B, Benito CC, Mcmullen M, Lungu I, Rossi SD, Msan A, Bowering V, Sotov V, Tran C, Butler MO, Oza AM, Diamandis P, Wang BX, Lheureux S. Elucidating divergent biology in uterine carcinosarcoma. Transl Oncol. 2025 Nov;61:102506.
11. Soleimani S, Li X, Wang BX, Pedersen S, Bruce JP, Eagles J, Liu ZA, Bratman SV, Butler MO, Hansen AR, Bedard PL, Lheureux S, Spreafico A, Razak A, Siu LL, Ohashi PS, Pugh TJ. T cell receptor repertoire in cell-free DNA as a proxy for tumor infiltrates in patients treated with pembrolizumab. Cell Rep. 2025 Sep 23;44(9):116190.
12. Liu S, Zheng C, Nechanitzky R, Luo P, Ramachandran P, Nguyen D, Elia AJ, Moghadas Jafari S, Law R, Snow BE, Wakeham AC, Berger T, Chen H, Gill KT, Mcwilliam R, Fortin J, Modares NF, Saunders ME, Murakami K, Qiu Y, You Z, Mohtashami M, Qi H, Ohashi PS, Zúñiga-Pflücker JC, Mak TW. Cholinergic regulation of thymocyte negative selection. Nat Immunol. 2025 Jun;26(6):881-893.

13. Wu Y, Wu BZ, Ellenbogen Y, Kant JBY, Yu P, Li X, Caloren L, Sotov V, Tran C, Restrepo M, Kushida M, Ayyadhury S, Kossinna P, Lau R, Habibi P, Mansouri S, Regala J, Durbic T, Aboualizadeh F, Tsao J, Ketela T, Pugh T, Butler MO, Wang BX, Dirks PB, Gao A, Zadeh G, Gaiti F. Neurodevelopmental hijacking of oligodendrocyte lineage programs drives glioblastoma infiltration. Dev Cell. 2025 May 13:S1534-5807(25)00260-6.

14. Lamorte S, Quevedo R, Jin R, Neufeld L, Liu ZQ, Ciudad MT, Lukhele S, Bruce J, Mishra S, Zhang X, Saeed ZK, Berman H, Philpott DJ, Girardin SE, Harding S, Munn DH, Mak TW, Karlsson MCI, Brooks DG, McGaha TL. Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33. Cancer Cell. 2025 May 12;43(5):955-969.e10.

15. Foffi E, Rugolo F, Ramamurthy N, Haight J, Helke S, You-Ten A, Tobin C, Jafari SM, Elia AJ, Berger T, Candi E, Melino G, Mak TW. B cell-derived acetylcholine mitigates skin inflammation in mice through α9 nicotinic acetylcholine receptor-mediated signaling. Proc Natl Acad Sci U S A. 2025 Apr 29;122(17):e2501960122.

16. Sanchez Vasquez JD, Nkongolo S, Traum D, Sotov V, Kim SC, Mahamed D, Mehrotra A, Patel A, Chen DY, Fung S, Gaggar A, Feld JJ, Chang KM, Wallin JJ, Wang BX, Janssen H, Gehring AJ. Virus-associated inflammation imprints an inflammatory profile on monocyte-derived macrophages in the human liver. J Clin Invest. 2025 Apr 15;135(8):e175241.

17. Chung DC, Shakfa N, Vakharia J, Warner K, Jacquelot N, Sayad A, Han S, Ghaedi M, Garcia-Batres CR, Sotty J, Azarmina A, Nowlan F, Chen ELY, Zon M, Elford AR, Wang BX, Nguyen LT, Mrkonjic M, Clarke BA, Bernardini MQ, Haibe-Kains B, Ferguson SE, Crome SQ, Jackson HW, Ohashi PS. CD103+CD56+ ILCs Are Associated with an Altered CD8+ T-cell Profile within the Tumor Microenvironment. Cancer Immunol Res. 2025 Apr 2;13(4):527-546.

18. Wong MK, Boukhaled GM, Armstrong E, Liu R, Heirali AA, Yee NR, Tsang J, Spiliopoulou P, Schneeberger PHH, Wang BX, Cochrane K, Sherriff K, Allen-Vercoe E, Siu LL, Spreafico A, Coburn B. Microbial Ecosystem Therapeutics 4 (MET4) elicits treatment-specific IgG responses associated with changes in gut microbiota in immune checkpoint inhibitor recipients with advanced solid tumors. J Immunother Cancer. 2025 Mar 22;13(3):e010681.

19. Shen Q, Murakami K, Sotov V, Butler M, Ohashi PS, Reedijk M. Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer. Sci Adv. 2024 Nov;10(44):eado8275.

20. Zhang C, Wu BZ, Di Ciano-Oliveira C, Wu YF, Khavkine Binstock SS, Soria-Bretones I, Pham NA, Elia AJ, Chari R, Lam WL, Bray MR, Mak TW, Tsao MS, Cescon DW, Thu KL. Identification of KIFC1 as a putative vulnerability in lung cancers with centrosome amplification. Cancer Gene Ther. 2024 Oct;31(10):1559-1570.

21. Zheng W, Marini W, Murakami K, Sotov V, Butler M, Gorrini C, Ohashi PS, Reedijk M. Caspase-1-dependent spatiality in triple-negative breast cancer and response to immunotherapy. Nat Commun. 2024 Oct 1;15(1):8514

22. Hernando-Calvo A, Han M, Ayodele O, Wang BX, Bruce JP, Abbas-Aghababazadeh F, Vila-Casadesús M, Sanz-Garcia E, Yang SYC, Berman HK, Vivancos A, Lam B, Lungu I, Salawu A, Stayner LA, Haibe-Kains B, Bedard PL, Avery L, Razak ARA, Pugh TJ, Spreafico A, Siu LL, Hansen AR. A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic Cancer. Clin Colorectal Cancer. 2024 Sep;23(3):272-284.

23. Chung DC, Garcia-Batres CR, Millar DG, Wong SWY, Elford AR, Mathews JA, Wang BX, Nguyen LT, Shaw PA, Clarke BA, Bernardini MQ, Sacher AG, Crome SQ, Ohashi PS. Generation of an Inhibitory NK Cell Subset by TGF-β1/IL-15 Polarization. J Immunol. 2024 Jun 15;212(12):1904-1912.

24. Hamidzada H, Pascual-Gil S, Wu Q, Kent GM, Massé S, Kantores C, Kuzmanov U, Gomez-Garcia MJ, Rafatian N, Gorman RA, Wauchop M, Chen W, Landau S, Subha T, Atkins MH, Zhao Y, Beroncal E, Fernandes I, Nanthakumar J, Vohra S, Wang EY, Sadikov TV, Razani B, McGaha TL, Andreazza AC, Gramolini A, Backx PH, Nanthakumar K, Laflamme MA, Keller G, Radisic M, Epelman S. Primitive macrophages induce sarcomeric maturation and functional enhancement of developing human cardiac microtissues via efferocytic pathways. Nat Cardiovasc Res. 2024 May;3(5):567-593.

25. Chung DC, Ghaedi M, Warner K, Sayad A, Saibil SD, Bernardini MQ, Clarke BA, Shaw PA, Butler MO, Easson A, Morrissy S, Wang BX, Nguyen L, Ohashi PS, Jacquelot N. Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors. Oncoimmunology. 2024 May 10;13(1):2349347.

26. Cunanan J, Rajyam SS, Sharif B, Udwan K, Rana A, De Gregorio V, Ricardo S, Elia A, Brooks B, Weins A, Pollak M, John R, Barua M. Mice with a Pax2 missense variant display impaired glomerular repair. Am J Physiol Renal Physiol. 2024 May 1;326(5):F704-F726.

27. Lien SC, Ly D, Yang SYC, Wang BX, Clouthier DL, St Paul M, Gadalla R, Noamani B, Garcia-Batres CR, Boross-Harmer S, Bedard PL, Pugh TJ, Spreafico A, Hirano N, Razak ARA, Ohashi PS. Tumor reactive γδ T cells contribute to a complete response to PD-1 blockade in a Merkel cell carcinoma patient. Nat Commun. 2024 Feb 6;15(1):1094.

28. Chua C, Salimzadeh L, Ma AT, Adeyi OA, Seo H, Boukhaled GM, Mehrotra A, Patel A, Ferrando-Martinez S, Robbins SH, La D, Wong D, Janssen HLA, Brooks DG, Feld JJ, Gehring AJ. IL-2 produced by HBV-specific T cells as a biomarker of viral control and predictor of response to PD-1 therapy across clinical phases of chronic hepatitis B. Hepatol Commun. 2023 Dec 7;7(12):e0337.

29. Salawu A, Wang BX, Han M, Geady C, Heirali A, Berman HK, Pfister TD, Hernando-Calvo A, Al-Ezzi EM, Stayner LA, Gupta AA, Ayodele O, Lam B, Hansen AR, Spreafico A, Bedard PL, Butler MO, Avery L, Coburn B, Haibe-Kains B, Siu LL, Abdul Razak AR. Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial. Clin Cancer Res. 2023 Oct 13;29(20):4128-4138.

30. Zheng C, Snow BE, Elia AJ, Nechanitzky R, Dominguez-Brauer C, Liu S, Tong Y, Cox MA, Focaccia E, Wakeham AC, Haight J, Tobin C, Hodgson K, Gill KT, Ma W, Berger T, Heikenwälder M, Saunders ME, Fortin J, Leung SY, Mak TW. Tumor-specific cholinergic CD4$^+$ T lymphocytes guide immunosurveillance of hepatocellular carcinoma. Nat Cancer. 2023 Oct;4(10):1437-1454.

31. Millar DG, Yang SYC, Sayad A, Zhao Q, Nguyen LT, Warner K, Sangster AG, Nakatsugawa M, Murata K, Wang BX, Shaw P, Clarke B, Bernardini MQ, Pugh T, Thibault P, Hirano N, Perreault C, Ohashi PS. Identification of antigenic epitopes recognized by tumor infiltrating lymphocytes in high grade serous ovarian cancer by multi-omics profiling of the auto-antigen repertoire. Cancer Immunol Immunother. 2023 Jul;72(7):2375-2392.

32. Spreafico A, Heirali AA, Araujo DV, Tan TJ, Oliva M, Schneeberger PHH, Chen B, Wong MK, Stayner LA, Hansen AR, Saibil SD, Wang BX, Cochrane K, Sherriff K, Allen-Vercoe E, Xu W, Siu LL, Coburn B. First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial). Ann Oncol. 2023 Jun;34(6):520-530.

33. Chavez JC, Foss FM, William BM, Brammer JE, Smith SM, Prica A, Zain JM, Tuscano JM, Shah H, Mehta-Shah N, Geethakumari PR, Wang BX, Zantinge S, Wang L, Zhang L, Boutrin A, Zhao W, Cheng L, Standifer N, Hewitt L, Enowtambong E, Shao W, Sharma S, Carlesso G, Moscow JA, Siu LL. Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma. Clin Cancer Res. 2023 May 15;29(10):1869-1878.

34. Leca J, Lemonnier F, Meydan C, Foox J, El Ghamrasni S, Mboumba DL, Duncan GS, Fortin J, Sakamoto T, Tobin C, Hodgson K, Haight J, Smith LK, Elia AJ, Butler D, Berger T, de Leval L, Mason CE, Melnick A, Gaulard P, Mak TW. IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment. Cancer Cell. 2023 Feb 13;41(2):323-339.e10.

35. Spiliopoulou P, Janse van Rensburg HJ, Avery L, Kulasingam V, Razak A, Bedard P, Hansen A, Chruscinski A, Wang B, Kulikova M, Chen R, Speers V, Nguyen A, Lee J, Coburn B, Spreafico A, Siu LL. Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy. Cell Death Dis. 2023 Jan 20;14(1):49.

36. Langille E, Al-Zahrani KN, Ma Z, Liang M, Uuskula-Reimand L, Espin R, Teng K, Malik A, Bergholtz H, Ghamrasni SE, Afiuni-Zadeh S, Tsai R, Alvi S, Elia A, Lü Y, Oh RH, Kozma KJ, Trcka D, Narimatsu M, Liu JC, Nguyen T, Barutcu S, Loganathan SK, Bremner R, Bader GD, Egan SE, Cescon DW, Sørlie T, Wrana JL, Jackson HW, Wilson MD, Witkiewicz AK, Knudsen ES, Pujana MA, Wahl GM, Schramek D. Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer. Cancer Discov. 2022 Dec 2;12(12):2930-2953.

37. Yanchus C, Drucker KL, Kollmeyer TM, Tsai R, Winick-Ng W, Liang M, Malik A, Pawling J, De Lorenzo SB, Ali A, Decker PA, Kosel ML, Panda A, Al-Zahrani KN, Jiang L, Browning JWL, Lowden C, Geuenich M, Hernandez JJ, Gosio JT, Ahmed M, Loganathan SK, Berman J, Trcka D, Michealraj KA, Fortin J, Carson B, Hollingsworth EW, Jacinto S, Mazrooei P, Zhou L, Elia A, Lupien M, He HH, Murphy DJ, Wang L, Abyzov A, Dennis JW, Maass PG, Campbell K, Wilson MD, Lachance DH, Wrensch M, Wiencke J, Mak T, Pennacchio LA, Dickel DE, Visel A, Wrana J, Taylor MD, Zadeh G, Dirks P, Eckel-Passow JE, Attisano L, Pombo A, Ida CM, Kvon EZ, Jenkins RB, Schramek D. A noncoding single-nucleotide polymorphism at 8q24 drives IDH1-mutant glioma formation. Science. 2022 Oct 7;378(6615):68-78.

38. Gadalla R, Boukhaled GM, Brooks DG, Wang BX. Mass cytometry immunostaining protocol for multiplexing clinical samples. STAR Protoc. 2022 Aug 22;3(3):101643.

39. Boukhaled GM, Gadalla R, Elsaesser HJ, Abd-Rabbo D, Quevedo R, Yang SYC, Guo M, Wang BX, Noamani B, Gray D, Lau SCM, Taylor K, Aung K, Spreafico A, Hansen AR, Saibil SD, Hirano N, Guidos C, Pugh TJ, McGaha TL, Ohashi PS, Sacher AG, Butler MO, Brooks DG. Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy. Nat Immunol. 2022 Aug;23(8):1273-1283.

40. Watson GA, Sanz-Garcia E, Zhang WJ, Liu ZA, Yang SC, Wang B, Liu S, Kubli S, Berman H, Pfister T, Genta S, Spreafico A, Hansen AR, Bedard PL, Lheureux S, Abdul Razak A, Cescon D, Butler MO, Xu W, Mak TW, Siu LL, Chen E. Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab. J Immunother Cancer. 2022 Jun;10(6):e004378.

41. Spiliopoulou P, Yang SYC, Bruce JP, Wang BX, Berman HK, Pugh TJ, Siu LL. All is not lost: learning from 9p21 loss in cancer. Trends Immunol. 2022 May;43(5):379-390.

42. Lheureux S, Matei DE, Konstantinopoulos PA, Wang BX, Gadalla R, Block MS, Jewell A, Gaillard SL, McHale M, McCourt C, Temkin S, Girda E, Backes FJ, Werner TL, Duska L, Kehoe S, Colombo I, Wang L, Li X, Wildman R, Soleimani S, Lien S, Wright J, Pugh T, Ohashi PS, Brooks DG, Fleming GF. Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. J Immunother Cancer. 2022 Mar;10(3):e004233.

43. Hui KK, Latif M, Soeandy CD, Huang S, Rodgers CE, Elia AJ, Henderson JT. Cisplatin toxicity in the developing brain displays an absolute requirement for caspase-3. Exp Neurol. 2022 May;351:114010.

44. Dojo Soeandy C, Elia AJ, Cao Y, Rodgers C, Huang S, Elia AC, Henderson JT. Necroptotic-Apoptotic Regulation in an Endothelin-1 Model of Cerebral Ischemia. Cell Mol Neurobiol. 2021 Nov;41(8):1727-1742.

45. Oliva M, Chepeha D, Araujo DV, Diaz-Mejia JJ, Olson P, Prawira A, Spreafico A, Bratman SV, Shek T, de Almeida J, R Hansen A, Hope A, Goldstein D, Weinreb I, Smith S, Perez-Ordoñez B, Irish J, Torti D, Bruce JP, Wang BX, Fortuna A, Pugh TJ, Der-Torossian H, Shazer R, Attanasio N, Au Q, Tin A, Feeney J, Sethi H, Aleshin A, Chen I, Siu L. Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study. J Immunother Cancer. 2021 Oct;9(10):e003476.

46. Jaiswal A, Murakami K, Elia A, Shibahara Y, Done SJ, Wood SA, Donato NJ, Ohashi PS, Reedijk M. Therapeutic inhibition of USP9x-mediated Notch signaling in triple-negative breast cancer. Proc Natl Acad Sci U S A. 2021 Sep 21;118(38):e2101592118.

47. Yang SYC, Lien SC, Wang BX, Clouthier DL, Hanna Y, Cirlan I, Zhu K, Bruce JP, El Ghamrasni S, Iafallo MAJ, Oliva M, Hansen AR, Spreafico A, Bedard PL, Lheureux S, Razak A, Speers V, Berman HK, Haibe-Kains B, Brooks DG, McGaha T, Butler M, Bratman SV, Ohashi PS, L Siu LL, Pugh TJ. Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. Nat Immunol. 2021 Aug;23(8):1273-1283.

48. Tran CW, Gold MJ, Garcia-Batres C, Tai K, Elford AR, Himmel ME, Elia AJ, Ohashi PS. Hypoxia-inducible factor 1 alpha limits dendritic cell stimulation of CD8 T cell immunity. PLoS One. 2020 Dec 31;15(12):e0244366.
49. Taylor K, Loo Yau H, Chakravarthy A, Wang B, Shen SY, Ettayebi I, Ishak CA, Bedard PL, Abdul Razak A, R Hansen A, Spreafico A, Cescon D, Butler MO, Oza AM, Lheureux S, Stjepanovic N, Van As B, Boross-Harmer S, Wang L, Pugh TJ, Ohashi PS, Siu LL, De Carvalho DD. An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors. J Immunother Cancer. 2020 Aug;8(2):e000883.
50. MacGregor HL, Sayad A, Elia A, Wang BX, Katz SR, Shaw PA, Clarke BA, Crome SQ, Robert-Tissot C, Bernardini MQ, Nguyen LT, Ohashi PS. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer. J Immunother Cancer. 2019; 2019 Dec 31;7(1):357.
51. MacGregor HL, Garcia-Batres C, Sayad A, Elia A, Berman HK, Toker A, Katz SR, Shaw PA, Clarke BA, Crome SQ, Robert-Tissot C, Bernardini MQ, Nguyen LT, Ohashi PS. Tumor cell expression of B7-H4 correlates with higher frequencies of tumor-infiltrating APCs and higher CXCL17 expression in human epithelial ovarian cancer. Oncoimmunology. 2019 Sep 30;8(12):e1665460.
52. Dojo Soeandy C, Salmasi F, Latif M, Elia AJ, Suo NJ, Henderson JT. Endothelin-1-mediated cerebral ischemia in mice: early cellular events and the role of caspase-3. Apoptosis. 2019 Aug;24(7-8):578-595.
53. Gadalla R, Noamani B, MacLeod B, Dickson R, Guo M, Xu W, Lukhele S, Elsaesser HJ, Razak A, Hirano N, McGaha TL, Wang BX, Butler M, Guidos CJ, Ohashi PS, Siu LL, Brooks DG. Validation of CyTOF against flow cytometry for immunological studies and monitoring of human cancer clinical trials. Front Oncol. 2019;9:415.
54. Jiang DM, Fyles A, Nguyen L, Neel B, Sacher A, Rottapel R, Wang BX, Ohashi PS, Sridhar SS. Phase I Study of Local Radiation and Tremelimumab in Patients with Inoperable Locally Recurrent or Metastatic Breast Cancer. Oncotarget. 2019;10(31):2947-2958.
55. Clouthier DL, Lien SC, Yang SYC, Nguyen LT, Manem VSK, Gray D, Ryczko M, Razak ARA, Lewin J, Lheureux S, Colombo I, Bedard PL, Cescon D, Spreafico A, Butler MO, Hansen AR, Jang RW, Ghai S, Weinreb I, Sotov V, Gadalla R, Noamani B, Guo M, Elston S, Giesler A, Hakgor S, Jiang H, McGaha T, Brooks DG, Haibe-Kains B, Pugh TJ, Ohashi PS, Siu LL. An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE). J Immunother Cancer. 2019 Mar 13;7(1):72.
56. Cox MA, Duncan GS, Lin GHY, Steinberg BE, Yu LX, Brenner D, Buckler LN, Elia AJ, Wakeham AC, Nieman B, Dominguez-Brauer C, Elford AR, Gill KT, Kubli SP, Haight J, Berger T, Ohashi PS, Tracey KJ, Olofsson PS, Mak TW. Choline acetyltransferase-expressing T cells are required to control chronic viral infection. Science. 2019 Feb 8;363(6427):639-644.